Narcolepsy Drug Doesn't Raise Odds for Birth Defects: Study
This study is based on twice as many pregnancies as earlier studies, and we... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 4, 2020 Category: General Medicine Source Type: news

Narcolepsy drug did not increase risk of fetal malformation
(Karolinska Institutet) Modafinil is used to treat conditions such as narcolepsy. Reports have associated the drug with an increased risk of malformation in babies born to mothers who had taken it while pregnant. Now, a large registry study involving over two million pregnant women in Sweden and Norway shows that there is no such association. The study, which is published in JAMA, was conducted by researchers at Sweden's Karolinska Institutet and the Norwegian Institute of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2020 Category: International Medicine & Public Health Source Type: news

'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 12, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

'Pay-for-delay' plan blocked cheap generic challengers to Peninsula company's narcolepsy drug for years, lawsuits claim
Legal maneuvering by the company effectively blocked a generic drug for narcolepsy from entering the market since 2011. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 12, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Can a peer support the process of self-management in narcolepsy? A qualitative narrative analysis of a narcoleptic patient - Franceschini C, Fante C, Filardi M, Folli MC, Brazzi F, Pizza F, D'Anselmo A, Ingravallo F, Antelmi E, Plazzi G.
INTRODUCTION: Narcolepsy type 1 (NT1) is a chronic and rare sleep disorder typically arising during adolescence and young adulthood. The main symptoms are excessive daytime sleepiness and cataplexy, a prototypical fall down elicited by huge emotions. Socia... (Source: SafetyLit)
Source: SafetyLit - August 3, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

FDA Okays Low-Sodium Treatment Option for Narcolepsy FDA Okays Low-Sodium Treatment Option for Narcolepsy
The novel drug Xywav is an oxybate product with a unique composition that results in 92% less sodium than sodium oxybate (Zyrem).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 22, 2020 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a curre... Biopharmaceuticals, Neurology, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news

Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav
The Food and Drug Administration has approved Jazz Pharmaceuticals' new drug application for Xywav, a new sleep disorder drug. Xywav was approved by the FDA, Tuesday night, to treat cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Jazz stock was up nearly 4.6% to $110.34 per share in early morning trading. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 22, 2020 Category: Biotechnology Authors: John George Source Type: news

FDA Approves Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2020 Category: Drugs & Pharmacology Source Type: news

Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management - Marinelli E, Beck R, Malvasi A, Faro AFL, Zaami S.
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal syndrome. The ... (Source: SafetyLit)
Source: SafetyLit - July 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

What Are the Signs of Narcolepsy
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 19, 2020 Category: General Medicine Source Type: news

A cautionary tale about narcolepsy and deferrals to the civilian network - Kinkennon S.
The transformation of Army medicine has been a topic of great concern for all military physicians, regardless of specialty. It has been proposed that 18,000 uniformed military medical personnel be cut (approximately 22% of 2019 uniformed personnel). Pe... (Source: SafetyLit)
Source: SafetyLit - March 11, 2020 Category: International Medicine & Public Health Tags: Commentary Source Type: news

Narcoleptic 15-year-old suffers sudden muscle paralysis if she giggles
Jordan Coomer, from Indiana, suffers from cataplexy, which causes sudden muscle paralysis if she giggles or feels strong emotion. It's a complication of narcolepsy, which can be caused by an infection. (Source: the Mail online | Health)
Source: the Mail online | Health - January 27, 2020 Category: Consumer Health News Source Type: news

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 22, 2020 Category: Drugs & Pharmacology Source Type: news

Jazz Pharmaceuticals sleep disorder drug approved by European Commission
The European Commission has approved Sunosi, a Jazz Pharmaceuticals sleep disorder treatment. Sunosi was approved, in 75- and 150-milligram doses, to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea who did not respond to primary sleep apnea therapies such as continuous positive airway pressure. Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has nearly 200 employees.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 21, 2020 Category: Biotechnology Authors: John George Source Type: news

Risk of burn injury in patients with narcolepsy: a nationwide population-based cohort study - Chang ET, Lin CL, Chen SF, Shen YC.
Narcolepsy is a rare brain disorder characterized by excessive daytime sleepiness (EDS), cataplexy, hypnagogic hallucinations, and sleep paralysis. Stimulants have been used to relieve the symptoms of EDS. Narcolepsy symptoms may pose a risk to burn injury... (Source: SafetyLit)
Source: SafetyLit - January 16, 2020 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea (OSA).International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Solriamfetol is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea If approved by the European Commission for... Biopharmaceuticals, Regulatory Jazz Pharmaceuticals, solriamfetol, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news

Novel, Low-Sodium Drug Promising for Narcolepsy Novel, Low-Sodium Drug Promising for Narcolepsy
A novel drug with a low-sodium formulation is both safe and effective for treating symptoms of narcolepsy in adult patients, results from a phase 3 trial suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 3, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

A case of a sleepy taxi driver presenting with narcolepsy - Miskoff JA, Chaudhri M.
Narcolepsy is a sleep disorder, which can manifest in childhood, or adolescence by causing excessive daytime sleepiness, hallucinations, sleep attacks or cataplexy. Although presentation can vary, nearly all patients present with excessive daytime sleepine... (Source: SafetyLit)
Source: SafetyLit - August 21, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
PLYMOUTH MEETING, PA, August 15, 2019— Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 15, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Okays Pitolisant (Wakix) for Narcolepsy FDA Okays Pitolisant (Wakix) for Narcolepsy
The FDA has approved pitolisant, a first-in-class, nonscheduled treatment option with a novel mechanism of action for adults with narcolepsy.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 15, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Harmony Biosciences Announces FDA Approval Of WAKIX(R) (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy
WAKIX represents the first and only non-scheduled treatment approved for patients with narcolepsy in the U.S. PLYMOUTH MEETING, Pa., Aug. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Harmony Biosciences, LLC (Harmony) announced today that the ... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, excessive daytime sleepiness, narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 15, 2019 Category: Pharmaceuticals Source Type: news

Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients - Antelmi E, Pizza F, Donadio V, Filardi M, Sosero YL, Incensi A, Vandi S, Moresco M, Ferri R, Marelli S, Ferini-Strambi L, Liguori R, Plazzi G.
To search for discriminating biomarkers, 30 patients with idiopathic rapid-eye-movements sleep behavior disorder (iRBD) were compared with 17 patients with RBD within narcolepsy type 1. Both groups underwent extensive examinations, including skin biopsy se... (Source: SafetyLit)
Source: SafetyLit - August 8, 2019 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Medical News Today: Everything you need to know about methylphenidate
Methylphenidate is a stimulant drug that doctors prescribe to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. Learn about how it works, its side effects, and typical dosages here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Medical News Today: Everything you need to know about Adderall
In this article, learn all about Adderall, a type of stimulant medication that doctors sometimes prescribe to treat ADHD or narcolepsy. We cover the uses, side effects, dosage, and more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Medical News Today: Is hair loss a side effect of Adderall?
Adderall is a combination drug for the short-term treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Although it is generally a safe and effective drug, it can cause a range of side effects. Alopecia, or hair loss, is a potential but uncommon side effect of taking Adderall. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

The risk of hospitalization for motor vehicle accident injury in narcolepsy and the benefits of stimulant use: a nationwide cohort study in Taiwan - Tzeng NS, Hsing SC, Chung CH, Chang HA, Kao YC, Mao WC, Yang CCH, Kuo TBJ, Chen TY, Chien WC.
STUDY OBJECTIVES: To examine the risk of hospitalization for motor vehicle accident injury (MVAI) in patients with narcolepsy and the effects of stimulant use on MVAI occurrence in patients with narcolepsy. METHODS: This is a population-based, retr... (Source: SafetyLit)
Source: SafetyLit - June 4, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Medical News Today: What are the side effects and risks of Ritalin?
Ritalin (methylphenidate) is a stimulant medication for the treatment of ADHD and narcolepsy. Ritalin can cause side effects and has the potential for misuse and addiction. Researchers are investigating the long-term safety and effectiveness of this drug in children and adolescents. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Personal trainer, 24, falls asleep up to 16 TIMES a day because of her narcolepsy
Belle Hutt, from Oxford, was terrified of her sudden sleep attacks because her condition also caused sleep paralysis and hallucinations. She now controls her sleeping with an exercise routine. (Source: the Mail online | Health)
Source: the Mail online | Health - May 29, 2019 Category: Consumer Health News Source Type: news

FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA approves Jazz Pharmaceutical sleep disorder drug
The Food and Drug Administration approved Jazz Pharmaceutical's new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea. Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval. Jazz Pharmaceuticals, which is based in Dublin, Ireland,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2019 Category: Biotechnology Authors: John George Source Type: news

FDA approves Jazz Pharmaceutical sleep disorder drug
The Food and Drug Administration approved Jazz Pharmaceutical's new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea. Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval. Jazz Pharmaceuticals, which is based in Dublin, Ireland,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 21, 2019 Category: American Health Authors: John George Source Type: news

FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2019 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Why narcolepsy is an autoimmune condition
New research finds an autoreactive type of immune cell related to narcolepsy, adding to the mounting body of evidence that the condition is autoimmune. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2019 Category: Consumer Health News Tags: Sleep / Sleep Disorders / Insomnia Source Type: news

FDA decision on Jazz Pharmaceuticals narcolepsy drug expected Wednesday
The Food and Drug Administration is expected to make a decision by Wednesday on a new drug application filed by Jazz Pharmaceuticals for its experimental narcolepsy drug solriamfetol. The FDA was originally set to make a ruling on the application in late December, but its review was extended by three months after the federal agency determined an submission made by Jazz during discussions regarding draft labeling for solriamfetol constituted a "major amendment" to its applicatio n. That resulted in… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 19, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

New proof that narcolepsy is an autoimmune disease
(University of Copenhagen The Faculty of Health and Medical Sciences) Researchers from the University of Copenhagen have discovered autoreactive cells in persons suffering from narcolepsy. This is a new, important proof that the sleep disorder is an autoimmune disease. This knowledge may lead to better treatment of the chronic condition, the researchers behind the new discovery believe. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 15, 2019 Category: Biology Source Type: news

Lannett stock up 6 percent following ADHD drug distribution deal
Lannett Co. Inc. entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of Adderall, a medicine prescribed to treat attention-deficit hyperactivity disorder and narcolepsy. Tim Crew, CEO of Lannett (NYSE: LCI), said the Northeast Philadelphia company plans to launch the generic version of Adderall in the "near term." He added Lannett is hopeful it can expand its relationship with Elite of Northvale, N.J., and SunGen of Princeton,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2019 Category: Biotechnology Authors: John George Source Type: news

Assessing readiness to drive in adolescents with narcolepsy: what are providers doing? - Ingram DG, Marciarille AM, Ehsan Z, Perry GV, Schneider T, Al-Shawwa B.
PURPOSE: There are no universally accepted guidelines for assessing driving readiness in adolescents with narcolepsy. The purpose of the present study was to survey pediatric sleep medicine providers regarding their current practice patterns for assessing ... (Source: SafetyLit)
Source: SafetyLit - February 11, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

A Third of Americans Are Sleep-Deprived. This Technology Could Help Them Rest Easier
Despite the fact that we spend roughly a third of our lives snoozing (or at least trying to), sleep is not well understood by scientists — to say nothing of the estimated 35% of Americans who don’t get enough of it. Part of the problem is how difficult it is to study slumber. Experiments currently require individuals to come into a hospital or laboratory, cover themselves with an army of electrodes and allow a team of doctors to observe their attempts to drift off. “It’s kind of a nightmare,” says Dr. Emmanuel Mignot, director of the Stanford Center for Sleep Sciences and Medicine. “They...
Source: TIME: Health - January 25, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Artificial Intelligence healthytime Life Reinvented Source Type: news

Nootropics, or ‘Smart Drugs,’ Are Gaining Popularity. But Should You Take Them?
The idea that a pill can supersize human intelligence is decidedly science fiction. But plenty of real-world researchers and drug-makers are working to develop nootropics: pills, supplements and other substances designed to improve various aspects of cognition. A rough translation for the word “nootropic” comes from the Greek for “to bend or shape the mind.” And already, there are dozens of over-the-counter (OTC) products—many of which are sold widely online or in stores—that claim to boost creativity, memory, decision-making or other high-level brain functions. Some of the most popular ...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Drugs Source Type: news

Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Dec. 21, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 21, 2018 Category: Drugs & Pharmacology Source Type: news

Sleep Disorder Drug May Be Effective for Stimulant Abuse Sleep Disorder Drug May Be Effective for Stimulant Abuse
Modafinil, a wakefulness-promoting agent approved for narcolepsy, obstructive sleep apnea, and shift work sleep disorder, shows promise in treating stimulant use disorders.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, Nov. 9, 2018 -- (Healthcare Sales & Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine... Biopharmaceuticals, Regulatory Jazz Pharmaceuticals, solriamfetol, narcolepsy, obstructive sleep apnea (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2018 Category: Pharmaceuticals Source Type: news

Solriamfetol Effective for Excessive Sleepiness in OSA, Narcolepsy Solriamfetol Effective for Excessive Sleepiness in OSA, Narcolepsy
The experimental drug solriamfetol appears to keep sleepy patients with narcolepsy or obstructive sleep apnea (OSA) awake and alert, according to an industry-sponsored trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Sodium Oxybate (Xyrem) for Pediatric Narcolepsy FDA Approves Sodium Oxybate (Xyrem) for Pediatric Narcolepsy
The FDA has approved expanded labeling for sodium oxybate (Xyrem) to include treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Alert Source Type: news

FDA Approves Xyrem (sodium oxybate) for Cataplexy and Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy
October 27, 2018 -- Today, the U.S. Food and Drug Administration (FDA) approved Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients (7 to 17 years old) with narcolepsy. Xyrem is a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 27, 2018 Category: Pharmaceuticals Source Type: news

Schoolgirl, 14, falls asleep up to 10 times a day and becomes paralysed when she laughs
Nicole Hirst, from Wakefield in Yorkshire, has narcolepsy, which means her brain cannot properly regulate when she falls asleep, leading to her nodding off multiple times a day. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2018 Category: Consumer Health News Source Type: news

What is the Difference Between Nightmares and Night Terrors?
Discussion Sleep disorders are common in all ages particularly with sleep deprivation in our increasingly busy world. Sleep problems are more common in patients with attention deficit hyperactivity disorder, epilepsy, headache and visual impairments. Sleep problems can cause cognitive and behavioral impairments including emotional regulation problems, increased seizures or headaches, and impaired attention and have been known to prolong recovery from various acquired brain injuries. Parasomnias are “undesirable events that accompany sleep and typically occur during sleep-wake transitions.” The term sleep terr...
Source: PediatricEducation.org - August 27, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Personal trainer with narcolepsy mistaken for a drunk
Belle Hutt, 23, who lives in Amsterdam, became a personal trainer after giving up her dream of working as an interior designer because she couldn't stay awake long enough for an office job. (Source: the Mail online | Health)
Source: the Mail online | Health - August 23, 2018 Category: Consumer Health News Source Type: news